Five Hypermethylated MicroRNA Genes as Potential Markers of Ovarian Cancer


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Только для подписчиков

Аннотация

MicroRNA and methylation are important epigenetic mechanisms in the pathogenesis of cancer. The role of a group of microRNA hypermethylated genes in the pathogenesis of ovarian cancer was studied and their diagnostic and prognostic potential was evaluated. Studies on a representative sample of 54 ovarian cancer specimens with the use of methyl-specific PCR resulted in detection of five microRNA genes (MIR-9-1, MIR-9-3, MIR-107, MIR-1258, and MIR-130b) methylated in the majority of tumor specimens in comparison with paired specimens of histologically intact tissue (37-57% vs. 4-9%, p<0.01). Methylation of three genes (MIR-9-1, MIR-9-3, and MIR-130b) was significantly (p≤0.05) associated with the parameters of ovarian cancer progress (clinical stage, differentiation degree, tumor size, and presence of metastases). These findings attest to oncosuppressive role of the studied microRNA genes (MIR-9-1, MIR-9-3, MIR-107, MIR-1258, and MIR-130b) in the pathogenesis and progress of ovarian cancer and indicated their prognostic potential.

Об авторах

E. Braga

Research Institute of Pathology and Pathophysiology; Research Centre of Medical Genetics

Автор, ответственный за переписку.
Email: eleonora10_45@mail.ru
Россия, Moscow; Moscow

V. Loginov

Research Institute of Pathology and Pathophysiology; Research Centre of Medical Genetics

Email: eleonora10_45@mail.ru
Россия, Moscow; Moscow

A. Burdennyi

Research Institute of Pathology and Pathophysiology

Email: eleonora10_45@mail.ru
Россия, Moscow

E. Filippova

Research Institute of Pathology and Pathophysiology

Email: eleonora10_45@mail.ru
Россия, Moscow

I. Pronina

Research Institute of Pathology and Pathophysiology

Email: eleonora10_45@mail.ru
Россия, Moscow

S. Kurevlev

Research Institute of Pathology and Pathophysiology

Email: eleonora10_45@mail.ru
Россия, Moscow

T. Kazubskaya

N. N. Blokhin Russian Cancer Research Center, the Ministry of Health of the Russian Federation

Email: eleonora10_45@mail.ru
Россия, Moscow

D. Kushlinskii

N. N. Blokhin Russian Cancer Research Center, the Ministry of Health of the Russian Federation

Email: eleonora10_45@mail.ru
Россия, Moscow

D. Utkin

N. N. Blokhin Russian Cancer Research Center, the Ministry of Health of the Russian Federation

Email: eleonora10_45@mail.ru
Россия, Moscow

V. Ermilova

N. N. Blokhin Russian Cancer Research Center, the Ministry of Health of the Russian Federation

Email: eleonora10_45@mail.ru
Россия, Moscow

N. Kushlinskii

N. N. Blokhin Russian Cancer Research Center, the Ministry of Health of the Russian Federation

Email: eleonora10_45@mail.ru
Россия, Moscow


© Springer Science+Business Media, LLC, part of Springer Nature, 2018

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах